Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.00−0.07 (-0.99%)
Close on Nov 19, 2026Market cap $462.35MP/E –Yield –
Evolus revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Evolus's revenue for the twelve months ending Jun 30, 2026 was $316.49M, up 13.9% year over year. For fiscal 2025 it was $297.18M, up 11.6% from the year before. The highest annual figure on record is $297.18M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $297.18M | +11.6% |
| FY2024 | Dec 31, 2024 | $266.27M | +31.8% |
| FY2023 | Dec 31, 2023 | $202.09M | +36.0% |
| FY2022 | Dec 31, 2022 | $148.62M | +49.1% |
| FY2021 | Dec 31, 2021 | $99.67M | +76.3% |
| FY2020 | Dec 31, 2020 | $56.54M | +61.9% |
| FY2019 | Dec 31, 2019 | $34.93M | – |
| FY2018 | Dec 31, 2018 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $84.08M | +21.2% |
| Q1 FY2026 | Mar 31, 2026 | $73.14M | +6.7% |
| Q4 FY2025 | Dec 31, 2025 | $90.30M | +14.4% |
| Q3 FY2025 | Sep 30, 2025 | $68.97M | +12.9% |
| Q2 FY2025 | Jun 30, 2025 | $69.39M | +3.7% |
| Q1 FY2025 | Mar 31, 2025 | $68.52M | +15.5% |
| Q4 FY2024 | Dec 31, 2024 | $78.95M | +29.4% |
| Q3 FY2024 | Sep 30, 2024 | $61.09M | +22.1% |
| Q2 FY2024 | Jun 30, 2024 | $66.91M | +35.6% |
| Q1 FY2024 | Mar 31, 2024 | $59.33M | +42.2% |
| Q4 FY2023 | Dec 31, 2023 | $61.00M | +39.8% |
| Q3 FY2023 | Sep 30, 2023 | $50.02M | +47.6% |
| Q2 FY2023 | Jun 30, 2023 | $49.35M | +32.8% |
| Q1 FY2023 | Mar 31, 2023 | $41.72M | +23.0% |
| Q4 FY2022 | Dec 31, 2022 | $43.65M | +25.9% |
| Q3 FY2022 | Sep 30, 2022 | $33.90M | +27.1% |
| Q2 FY2022 | Jun 30, 2022 | $37.16M | +42.4% |
| Q1 FY2022 | Mar 31, 2022 | $33.91M | +177.0% |
| Q4 FY2021 | Dec 31, 2021 | $34.66M | +68.4% |
| Q3 FY2021 | Sep 30, 2021 | $26.68M | +51.1% |
| Q2 FY2021 | Jun 30, 2021 | $26.10M | +234.3% |
| Q1 FY2021 | Mar 31, 2021 | $12.24M | +16.6% |
| Q4 FY2020 | Dec 31, 2020 | $20.58M | +5.8% |
| Q3 FY2020 | Sep 30, 2020 | $17.66M | +34.1% |
| Q2 FY2020 | Jun 30, 2020 | $7.81M | +237.8% |
| Q1 FY2020 | Mar 31, 2020 | $10.50M | – |
| Q4 FY2019 | Dec 31, 2019 | $19.45M | – |
| Q3 FY2019 | Sep 30, 2019 | $13.17M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.31M | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
See a number that looks wrong?